We are taking a systems approach to vaccine development that is rooted in science and driven by first principles. This approach, which integrates nanotechnology, materials science, immunology, clinical science, and social science, will transform the design and manufacture of vaccines and enable rapid commercialization by encompassing bench-to-bedside considerations from the earliest stages of conceptualization.
Our systems framework is based on five tightly integrated research thrusts:
Thrust 1: Novel antigen design and production
Thrust 2: Nanoscale adjuvants and delivery systems
Thrust 3: Vaccine efficacy and immunological mechanisms
Thrust 4: Scale-up, cGMP (current Good Manufacturing Practice) devices, and clinical testing
Thrust 5: Global deployability and economic analysis
These thrusts will be integrated to design nanovaccines against respiratory infections, tropical diseases, neurodegenerative disorders, cancer, diseases and conditions related to aging, and veterinary diseases. Our research will fill major gaps in basic research on vaccines and pre-clinical studies that lay the foundation for clinical trials.